Galectin-3/β-catenin may be a novel mechanism contributing to the initiation and maintenance of lung CSCs, suggesting that targeting galectin-3 may provide an innovative strategy worth considering for lung cancer therapy. Here, LGALS3 is linked to lung carcinoma.